Treatment of congenital cytomegalovirus: where are we now?
Congenital cytomegalovirus (CMV) is the most common congenital infection in the USA, affecting approximately 1% of all live births. While the majority of infants will remain asymptomatic, approximately 10% will be symptomatic at birth and another 10-15% will go on to develop problems during the first 6 years of life. Congenital CMV is now the most common cause of nonhereditary sensorineural hearing loss in children. Accordingly, researchers and clinicians have long been interested in identifying strategies to prevent or treat symptomatic congenital CMV infection. This article reviews congenital CMV with a focus on treatment strategies.
Michaels
Marian G
MG
University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Division of Infectious Diseases, Pittsburgh PA 15213, USA. marian.michaels@chp.edu
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077404:Cidofovir; D003586:Cytomegalovirus Infections / Q000151:congenital* / Q000188:drug therapy* / Q000453:epidemiology; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D000077562:Valganciclovir
D000998:Antiviral Agents; D063065:Organophosphonates; D017245:Foscarnet; D003596:Cytosine; D000077562:Valganciclovir; D000077404:Cidofovir; D015774:Ganciclovir